Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17743904 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL17743907 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL17743818 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL17743902 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL17743822 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL16391027 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL17743820 | 1.00 | FFAR1 (0.57) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL31628727 | 0.94 | TRPV1 (0.54) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL830444 | 0.91 | TRPV1 (0.52) | FFAR1FFAR4TRPV1FAAHPRKCA | |
| SCHEMBL7531489 | 0.91 | TRPV1 (0.52) | FFAR1FFAR4TRPV1FAAHPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10731159-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10731159-B2 | Cationic lipid | CETP, NPC1L1, LIPA | FFAR1 161/4885FFAR4 175/4885TRPV1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.